Abstract 905P
Background
Recently, ASCO and ESMO guidelines on Salivary Gland Carcinomas (SGCs) have been released. Several crucial points lack strong recommendations, due to low or intermediate quality of evidence. We conducted a survey in the EORTC Head and Neck Cancer Group (HNCG) members, on behalf of the EORTC Young and Early Career Investigator to better address such “grey zones” of the guidelines.
Methods
The survey included 29 questions, covering diagnostic and therapeutic issues of SGC patients and was shared among 539 members of the EORTC HNCG. Responses were collected from December 2022 to March 2023. The primary aim was to evaluate decision criteria guiding physician’s on areas of low evidence of SGCs guidelines.
Results
Among 102 responders, aged 40-55 years (55%), 45%, 28%, 22%, and 5% were medical oncologists, radiation oncologists, ENT surgeons, and other specialists, respectively. Respondents were distributed across Europe (mainly Italy 19%, Belgium 10%, and Spain 8%). Chemoradiotherapy (CRT) in the definitive and adjuvant (adj) settings in case of pathological high risk features was recommended by 35% and 30% of them, respectively. In case of R0 resection of highly aggressive SGC, at pT1-2 stage, 37% proposed close follow up, while 38% proposed adj lymph node (LN) field RT; for pT3-4 stage, 48% proposed adj LN field RT in all cases, and 44% proposed adj LN field RT only based on risk factors. After salvage surgery for locoregional relapse, the most important factors guiding decision to give adj RT were previous radiotherapy, margin status, and presence of extranodal extension. Fifty% of respondents would propose adjuvant antiHER2 or anti androgen receptor (AR) treatment within clinical trial (if positive receptor status). In case of combined positivity to HER2 and AR, responses were heterogeneous regarding the choice for first-line treatment.
Conclusions
Due to a lack of high-level evidence, international guidelines do not provide strong recommendations in several fields of SGCs diagnosis and treatment, contributing to inconsistent approaches in clinical practice. Further prospective trials are required to better address these topics.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
878P - INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Presenter: Simon Laban
Session: Poster session 12
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
885P - Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma
Presenter: Dingyi Wang
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12